Dr. Kamran on including immunotherapy in bladder-preservation therapy
“The NRG SWOG 1806 trial is a phase 3 trial randomizing patients to standard trimodality therapy or trimodality therapy plus atezolizumab,” says Sophia Kamran, MD.
Sophia Kamran, MD, discusses the potential of adding immune-checkpoint inhibitors, such as the PD-L1 inhibitor atezolizumab (Tecentriq) to bladder-preservation, or “trimodal,” therapy for patients with bladder cancer. Kamran is a radiation oncologist at Massachusetts General Hospital and assistant professor of Radiation Oncology at Harvard Medical School.
Updates on advanced bladder cancer treatment
October 30th 2023"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
